---
title: "Bispecific competition, debating oral SERDs and a bold GLP-1 prediction"
date: Mon, 02 Jun 2025 14:12:00 -0400
source: "BioPharmaDive"
link: "https://www.biopharmadive.com/news/asco-2025-pd1-vegf-bispecifics-oral-serds-hpv-vaccination/749498/"
---

<figure><div><img src="https://imgproxy.divecdn.com/8m2UUy2QBRQsGJIHWjhIc6YLzal_YHYoOaoVXxoJxYI/g:nowe:0:592/c:3200:1807/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9JTUdfMjg1NF9IQm41Q0loLmpwZw==.webp" /></div></figure><p>Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use a new crop of breast cancer medicines.</p>